Cardinal Health (CAH): Q2 Earnings, Strategic Acquisitions, and Navigating Healthcare's Evolving Landscape#
Cardinal Health (CAH) recently reported its Q2 2025 earnings, exceeding EPS expectations but facing revenue challenges due to the OptumRx contract expiry. Analysts are generally positive, raising price targets and highlighting the stock's value. Strategic acquisitions like GI Alliance and Advanced Diabetes Supply Group aim to drive future growth. While a quarterly dividend signals financial stability, negative cash flow metrics remain a concern. Cardinal Health is adapting to telehealth trends and managing supply chain complexities to maintain its competitive edge.
Cardinal Health's Q2 2025 Earnings: A Detailed Analysis#
Cardinal Health (CAH) recently released its second-quarter fiscal year 2025 results, showcasing a mixed financial performance. While the company reported better-than-expected earnings per share (EPS), revenue figures presented a more nuanced picture, impacted by both positive and negative factors. The company's stock price as of February 21, 2025, is $128.415, near its 52-week high, reflecting investor optimism following the earnings release.
Specifically, revenue decreased by 4% to $55.3 billion compared to the second quarter of fiscal year 2024. However, excluding the impact of a previously communicated large customer contract expiration, revenue actually increased by a substantial 16%. This highlights the significant impact of the contract loss and the underlying growth in other areas of the business. According to Monexa AI, the large customer contract expiration refers to the OptumRx contract expiry.
On the profitability front, GAAP operating earnings were reported at $549 million, with a GAAP diluted EPS of $1.65. Non-GAAP figures showed even stronger performance, with operating earnings increasing by 9% to $635 million, driven primarily by the Pharmaceutical and Specialty Solutions segment. The non-GAAP diluted EPS increased by 2% to $1.93, exceeding analyst expectations. This suggests that Cardinal Health is effectively managing its costs and improving its operational efficiency, despite the revenue headwinds.
The Pharmaceutical segment, a core component of Cardinal Health's business, experienced both positive and negative influences during the quarter. While the segment benefited from overall growth in pharmaceutical distribution, it was significantly impacted by the expiration of the OptumRx contract. This contract loss led to a decline in revenue, partially offsetting the gains from other areas. The expiration of the OptumRx contract continues to be a significant headwind for Cardinal Health, impacting its Pharmaceutical segment sales, according to Monexa AI.
Conversely, the Medical segment demonstrated robust growth, driven by increased demand for Cardinal Health branded medical, surgical, and laboratory products. This segment continues to benefit from the company's focus on manufacturing and distributing its own branded products, which offer higher margins and greater control over the supply chain. The new Kendall SCD Smartflow™ Compression System, launched in November 2024, is expected to contribute to future growth in this segment. The Kendall™ SCD SMARTFLOW™ COMPRESSION SYSTEM delivers customized, intermittent pneumatic compression (IPC) to increase blood flow in at-risk patients, the KENDALL SCD SMARTFLOW™ SYSTEM is designed to help prevent venous thromboembolism (VTE) events, as well as enhance blood circulation and treat pain and swelling related to venous stasis, according to a Cardinal Health Press Release.
Looking ahead, Cardinal Health has raised its fiscal year 2025 non-GAAP EPS guidance to a range of $7.85 to $8.00, up from the previous guidance of $7.75 to $7.90. This reflects the company's confidence in its ability to continue driving profitability, despite the ongoing challenges. The raised guidance suggests that Cardinal Health is effectively executing its strategic plan and is well-positioned to capitalize on future growth opportunities.
The company also announced the completion of its acquisition of a 73% ownership stake in GI Alliance, a leading gastroenterology (GI) management services organization (MSO). This acquisition is expected to significantly expand Cardinal Health's presence in the specialty pharmaceutical market and provide access to a large network of physicians and patients. The GI Alliance acquisition aligns with Cardinal Health's strategy of diversifying its revenue streams and focusing on high-growth areas of the healthcare market.
Analyst Sentiment and Stock Performance#
Following the release of Cardinal Health's Q2 2025 earnings, several Wall Street analysts have updated their price targets and ratings for the company's stock (CAH). The general sentiment among analysts is positive, with many raising their forecasts to reflect the better-than-expected earnings and the company's strategic initiatives. According to Monexa AI, analysts are raising their forecasts for Cardinal Health following better-than-expected Q2 2025 financial results.
For example, analysts at Benzinga noted that Cardinal Health's Q2 earnings beat estimates, leading to increased EPS views for 2025. This positive assessment has contributed to a rise in analyst confidence and a corresponding increase in price targets. Similarly, Zacks.com highlighted Cardinal Health as a potentially undervalued stock, suggesting that investors may be undervaluing the company's long-term growth potential. Several articles suggest Cardinal Health is a potentially undervalued stock and a strong value stock, according to Monexa AI.
UBS Group, as reported by MarketBeat.com, increased its price target for CAH from $134 to $139, indicating a belief that the stock has further upside potential. This upgrade reflects the analyst's positive outlook on Cardinal Health's future performance and its ability to generate sustainable growth. The consensus among analysts is that Cardinal Health is a solid investment with a strong value proposition.
Recent articles from Zacks.com suggest that Cardinal Health is not only a strong value stock but also a potentially undervalued asset. This assessment is based on the Zacks Rank system, which emphasizes earnings estimates and estimate revisions to identify promising investment opportunities. The fact that Cardinal Health is being recognized as a value stock indicates that it may be trading at a discount to its intrinsic value.
Several factors contribute to this perception of undervaluation. First, Cardinal Health's consistent dividend payouts make it an attractive investment for income-seeking investors. The company's board recently approved a quarterly dividend of $0.5056 per share, demonstrating its commitment to returning value to shareholders. Second, Cardinal Health's strategic acquisitions and expansion initiatives are expected to drive long-term growth and profitability.
However, it's important to note that the company also faces certain challenges, such as the OptumRx contract expiry and negative cash flow metrics. These factors may be contributing to the perception of undervaluation, as investors may be factoring in these risks when assessing the company's stock price.
The stock market's response to Cardinal Health's recent performance has been largely positive, with the stock trading near its 52-week high. This reflects investor optimism following the Q2 2025 earnings release and the company's strategic announcements.
However, it's important to note that the stock's performance is also influenced by broader market trends and economic conditions. The healthcare sector, in general, has been performing well in recent months, driven by factors such as an aging population and increased demand for healthcare services. This positive trend has likely contributed to the favorable sentiment surrounding Cardinal Health's stock.
Strategic Acquisitions: GI Alliance and Advanced Diabetes Supply Group#
Cardinal Health (CAH) has recently made two significant strategic acquisitions that are expected to drive future growth and expand its presence in key areas of the healthcare market. These acquisitions include a majority stake in GI Alliance, a leading gastroenterology (GI) management services organization (MSO), and the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies. According to Monexa AI, Cardinal Health is expanding into Gastroenterology with GI Alliance Acquisition.
The acquisition of GI Alliance is particularly noteworthy, as it represents a significant expansion into the specialty pharmaceutical market. GI Alliance supports over 900 physicians in 345 practices across 20 states, providing Cardinal Health with access to a large network of healthcare providers and patients. This acquisition is expected to enhance Cardinal Health's multi-specialty growth strategy and accelerate its expansion into the gastroenterology market.
According to Cardinal Health's press release on November 11, 2024, the GI Alliance acquisition will add the country's leading gastroenterology (GI) management services organization (MSO) to Cardinal Health's specialty portfolio, supporting over 900 physicians in 345 practices in 20 states. This demonstrates the scale and reach of GI Alliance and the potential synergies with Cardinal Health's existing business.
The acquisition of the Advanced Diabetes Supply Group is another strategic move that aligns with Cardinal Health's focus on at-home healthcare solutions. The Advanced Diabetes Supply Group is a leading national direct-to-patient provider of diabetes medical supplies, serving a large and growing market. This acquisition is expected to accelerate Cardinal Health's at-home solutions growth strategy and enhance its ability to serve patients in the comfort of their own homes.
The at-home healthcare market is experiencing rapid growth, driven by factors such as an aging population, increased demand for telehealth services, and a growing preference for receiving care in the home. By acquiring the Advanced Diabetes Supply Group, Cardinal Health is well-positioned to capitalize on this trend and expand its presence in the at-home healthcare market.
According to Cardinal Health's press release on November 11, 2024, the acquisition of the Advanced Diabetes Supply Group will accelerate Cardinal Health's at-home solutions growth strategy. This highlights the strategic importance of this acquisition and its potential to drive future growth.
Both the GI Alliance and Advanced Diabetes Supply Group acquisitions are expected to generate significant synergies with Cardinal Health's existing business. These synergies include increased revenue, improved profitability, and enhanced operational efficiency.
Cardinal Health plans to integrate the acquired companies into its existing infrastructure and leverage its expertise in supply chain management, distribution, and specialty pharmaceutical services to drive growth and create value. The company is also committed to investing in these businesses to support their continued expansion and innovation.
The successful integration of these acquisitions will be critical to Cardinal Health's future success. The company has a proven track record of successfully integrating acquired companies, and it is confident in its ability to achieve the expected synergies from these transactions.
Dividend Approval Signals Confidence in Financial Stability#
On February 3, 2025, Cardinal Health's (CAH) Board of Directors approved a quarterly dividend of $0.5056 per share, demonstrating the company's confidence in its financial stability and commitment to returning value to shareholders. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. According to Monexa AI, Dividend Approval Signals Confidence in Financial Stability.
Consistent dividend payouts are a hallmark of financially stable and well-managed companies. The fact that Cardinal Health continues to pay a regular dividend, even in the face of certain challenges, is a positive sign for investors. It indicates that the company has a strong cash flow and is committed to rewarding its shareholders.
The dividend announcement also reflects the Board's confidence in the company's future prospects. The Board likely believes that Cardinal Health is well-positioned to continue generating strong earnings and cash flow, allowing it to sustain its dividend payments over the long term.
Cardinal Health's dividend yield, which is the annual dividend payment divided by the stock price, is an important metric for income-seeking investors. A higher dividend yield indicates that the investor is receiving a greater return on their investment in the form of dividend payments.
As of February 21, 2025, Cardinal Health's dividend yield is approximately 1.57%. While this may not be the highest dividend yield in the market, it is still a respectable return, especially considering the company's financial stability and growth potential.
The dividend yield is also influenced by the stock price. As the stock price increases, the dividend yield decreases, and vice versa. Therefore, investors should consider both the dividend payment and the stock price when assessing the attractiveness of Cardinal Health's dividend.
Cardinal Health's dividend payout ratio, which is the percentage of earnings paid out as dividends, is another important metric to consider. A lower payout ratio indicates that the company is retaining a larger portion of its earnings for reinvestment in the business, which can drive future growth.
As of February 21, 2025, Cardinal Health's payout ratio is approximately 37.7%. This is a relatively healthy payout ratio, indicating that the company is balancing its commitment to dividend payments with its need to reinvest in the business.
The payout ratio can also be an indicator of dividend sustainability. A company with a very high payout ratio may be at risk of cutting its dividend in the future if its earnings decline. However, Cardinal Health's relatively low payout ratio suggests that its dividend is sustainable, even in the face of certain challenges.
Supply Chain and Distribution Network Expansion#
Cardinal Health (CAH) is investing in expanding and modernizing its supply chain and distribution network to enhance its operational efficiency and better serve its customers. A key component of this strategy is the construction of a new distribution center in Fort Worth, Texas, which will support the company's at-home solutions business. According to Monexa AI, New Distribution Center to Boost At-Home Solutions Business.
The new distribution center, announced on January 14, 2025, will consolidate two existing warehouses into one larger facility, creating approximately 74,000 additional square feet of inventory capacity. This expansion will allow Cardinal Health to better manage its inventory, reduce lead times, and improve its ability to meet the growing demand for at-home healthcare solutions.
The Fort Worth distribution center will be outfitted with the latest robotics and automation technologies, further enhancing its efficiency and productivity. This investment in technology demonstrates Cardinal Health's commitment to innovation and its willingness to embrace new solutions to improve its operations.
Cardinal Health's distribution network is a critical component of its competitive advantage. The company has a vast network of distribution centers and warehouses across the United States, allowing it to efficiently serve a wide range of customers, including hospitals, pharmacies, and physician offices.
According to Wikipedia, Cardinal Health serves more than 75% of hospitals in the U.S. This demonstrates the company's extensive reach and its importance to the healthcare industry. The company's ability to efficiently distribute pharmaceutical and medical products is essential to ensuring that patients have access to the medications and supplies they need.
The company's strategic acquisitions, such as GI Alliance and the Advanced Diabetes Supply Group, are expected to further enhance its distribution capabilities and expand its reach into new markets.
Cardinal Health is also focused on improving its supply chain management practices to reduce costs and mitigate risks. The company is implementing new technologies and processes to optimize its inventory levels, improve its forecasting accuracy, and enhance its collaboration with suppliers.
Supply chain disruptions have become a major concern for companies across all industries, including the healthcare industry. Cardinal Health is taking proactive steps to address this challenge by diversifying its supply base, building redundancy into its supply chain, and investing in technology to improve its visibility and control over its supply chain.
The company's digitally automated, clinically integrated supply chains can reduce the time spent obtaining supplies, further enhancing its efficiency and responsiveness to customer needs.
Challenges and Risks: OptumRx Contract Expiry and Cash Flow Concerns#
One of the major challenges facing Cardinal Health (CAH) is the expiration of the OptumRx contract, which has negatively impacted its Pharmaceutical segment sales. The loss of this contract has led to a decline in revenue and has put pressure on the company's earnings. According to Monexa AI, OptumRx Contract Expiry: Impact and Mitigation Strategies.
Cardinal Health is implementing strategies to mitigate the impact of the OptumRx contract expiry, including focusing on growth in other areas of the business, diversifying its customer base, and managing its costs. However, it is unlikely that the company will be able to fully offset the revenue loss in the short term.
The company's Q2 2025 earnings release highlighted the impact of the OptumRx contract expiry, noting that revenue decreased by 4% due to the contract loss. This underscores the significance of this challenge and its potential impact on Cardinal Health's future performance.
Another area of concern is Cardinal Health's negative operating cash flow per share and free cash flow per share. These metrics indicate that the company is not generating enough cash from its operations to cover its expenses and investments. According to Monexa AI, Cash Flow Concerns Amidst Earnings Growth.
As of February 21, 2025, Cardinal Health's operating cash flow per share is -0.0785, and its free cash flow per share is -2.119. These negative figures raise questions about the company's financial health and its ability to invest in future growth.
Cardinal Health is taking steps to address this issue, including improving its working capital management, reducing its capital expenditures, and focusing on generating more cash from its operations. However, it may take some time for these efforts to bear fruit.
In addition to the OptumRx contract expiry and cash flow concerns, Cardinal Health also faces other risks and challenges, including pricing pressures in the healthcare distribution sector, operational issues in its Global Medical Products and Distribution (GMPD) segment, and the potential impact of healthcare reform initiatives.
The healthcare distribution sector is highly competitive, with several large players vying for market share. This competition puts pressure on prices and margins, making it difficult for companies like Cardinal Health to generate strong profits.
The company must also navigate a complex regulatory landscape and adapt to changes in healthcare policy. Healthcare reform initiatives, such as the Affordable Care Act, can have a significant impact on the healthcare industry and on Cardinal Health's business.
Cardinal Health Navigates Supply Chain Challenges#
In today's interconnected world, supply chain resilience is paramount, especially for a company like Cardinal Health (CAH) that operates at the heart of healthcare. Geopolitical instability, natural disasters, and economic fluctuations can all disrupt the flow of essential medical supplies, impacting patient care.
Cardinal Health is proactively addressing these challenges by diversifying its sourcing strategies, investing in advanced inventory management systems, and fostering strong relationships with its suppliers. By building a more agile and responsive supply chain, the company aims to minimize disruptions and ensure a consistent supply of critical products.
Furthermore, Cardinal Health is leveraging technology to enhance supply chain visibility and improve forecasting accuracy. By gaining real-time insights into demand patterns and potential bottlenecks, the company can make informed decisions and proactively address potential disruptions.
Inflation poses a significant threat to Cardinal Health's profitability, as rising costs for raw materials, transportation, and labor can erode margins. The company is actively managing these inflationary pressures by implementing cost-saving initiatives, negotiating favorable contracts with suppliers, and optimizing its pricing strategies.
Cardinal Health is also exploring opportunities to streamline its operations and improve efficiency, further reducing its cost base. By carefully managing its expenses and maximizing its operational effectiveness, the company aims to mitigate the impact of inflation and maintain its profitability.
The company's size and scale provide it with significant negotiating power, allowing it to secure favorable terms with its suppliers and mitigate some of the inflationary pressures. However, ongoing vigilance and proactive management are essential to navigate the evolving economic landscape.
Cardinal Health recognizes the importance of sustainability and ethical sourcing in today's business environment. The company is committed to responsible sourcing practices, ensuring that its suppliers adhere to high ethical and environmental standards.
Cardinal Health is also working to reduce its environmental footprint by implementing energy-efficient technologies, reducing waste, and promoting sustainable transportation practices. By embracing sustainability, the company aims to create long-term value for its stakeholders and contribute to a healthier planet.
The company's commitment to ethical sourcing and sustainability is not only the right thing to do but also a strategic imperative. Consumers and investors are increasingly demanding that companies operate responsibly, and Cardinal Health is committed to meeting these expectations.
Telehealth and the Future of Pharmaceutical Distribution#
Telehealth is revolutionizing the healthcare industry, transforming the way patients access care and manage their health. Cardinal Health (CAH) is actively adapting to this changing landscape by developing new solutions and services that support telehealth providers and patients.
The company is working to integrate its pharmaceutical distribution capabilities with telehealth platforms, enabling patients to receive their medications and medical supplies directly at home. This seamless integration enhances the patient experience and improves access to care, particularly for those in remote or underserved areas.
Cardinal Health is also exploring opportunities to provide telehealth providers with access to its extensive network of pharmacies and healthcare professionals, further enhancing the value of its services.
Personalized medicine is another emerging trend that is transforming the pharmaceutical industry. Cardinal Health is investing in capabilities to support personalized medicine, including specialty pharmacy services, genetic testing, and data analytics.
Specialty pharmacies play a critical role in dispensing and managing complex medications for patients with chronic conditions. Cardinal Health is expanding its specialty pharmacy capabilities to meet the growing demand for these specialized services.
The company is also leveraging data analytics to identify patients who may benefit from personalized medicine approaches and to optimize treatment plans. By harnessing the power of data, Cardinal Health aims to improve patient outcomes and reduce healthcare costs.
The increasing adoption of digital technologies is transforming the entire healthcare industry, from patient engagement to supply chain management. Cardinal Health is embracing these digital technologies to improve its operations and better serve its customers.
The company is investing in mobile apps, online portals, and other digital tools to enhance patient engagement and improve communication between patients and healthcare providers. These digital tools empower patients to take control of their health and make informed decisions.
Cardinal Health is also leveraging digital technologies to improve its supply chain management, reduce costs, and enhance its customer service. By embracing digital transformation, the company aims to stay ahead of the curve and maintain its competitive edge.
Cardinal Health's Competitive Edge in a Changing Market#
Cardinal Health (CAH) operates in a highly competitive market, facing challenges from other large pharmaceutical distributors, specialty pharmacies, and healthcare service providers. To maintain its competitive edge, the company is focused on several key strategies.
These strategies include investing in innovation, expanding its specialty portfolio, improving its operational efficiency, and enhancing its customer service. By excelling in these areas, Cardinal Health aims to differentiate itself from its competitors and maintain its leading position in the market.
The company's strategic acquisitions, such as GI Alliance and the Advanced Diabetes Supply Group, are also expected to enhance its competitive position and expand its reach into new markets.
Cardinal Health's vast distribution network is a significant competitive advantage. The company has a well-established network of distribution centers and warehouses across the United States, allowing it to efficiently serve a wide range of customers.
This extensive distribution network provides Cardinal Health with a scale and reach that its competitors struggle to match. The company's ability to efficiently distribute pharmaceutical and medical products is essential to ensuring that patients have access to the medications and supplies they need.
The new distribution center in Fort Worth, Texas, will further enhance Cardinal Health's distribution capabilities and improve its ability to serve its customers.
Cardinal Health's strong relationships with its customers are another key competitive advantage. The company has built long-term relationships with hospitals, pharmacies, physician offices, and other healthcare providers, based on trust and mutual benefit.
These relationships provide Cardinal Health with valuable insights into its customers' needs and preferences. The company uses this information to tailor its products and services to meet the specific requirements of its customers.
Cardinal Health is also committed to providing excellent customer service, ensuring that its customers are satisfied with its products and services. This commitment to customer satisfaction helps to build loyalty and strengthen its relationships with its customers.
Cash Flow Concerns Amidst Earnings Growth#
While Cardinal Health (CAH) has demonstrated strong earnings growth, it's important to acknowledge concerns about its negative operating cash flow per share and free cash flow per share. As of February 21, 2025, the company's operating cash flow per share is -0.0785, and its free cash flow per share is -2.119. These negative figures raise questions about the company's financial health and its ability to invest in future growth.
Negative cash flow can stem from various factors, including the timing of payments, changes in working capital, and investments in growth initiatives. It's crucial to understand the root causes of these negative cash flow metrics and how Cardinal Health plans to address them.
Investors will likely scrutinize future earnings releases for improvements in cash flow metrics, as sustainable earnings growth requires healthy cash generation.
Cardinal Health is actively working to improve its cash flow by implementing several strategies. These strategies include:
- Optimizing working capital management to reduce the amount of cash tied up in inventory and accounts receivable.
- Reducing capital expenditures by focusing on high-return investments.
- Improving its forecasting accuracy to better manage its inventory levels.
- Enhancing its collaboration with suppliers to negotiate favorable payment terms.
The company is also exploring opportunities to generate more cash from its operations by increasing its sales, improving its margins, and reducing its costs. By implementing these strategies, Cardinal Health aims to improve its cash flow and strengthen its financial position.
Cardinal Health's management team is confident in its ability to improve the company's cash flow over time. The company is committed to investing in its business, but it is also focused on managing its expenses and generating strong cash flow.
The management team believes that the company's strategic acquisitions, such as GI Alliance and the Advanced Diabetes Supply Group, will contribute to its cash flow growth in the long term. These acquisitions are expected to generate significant synergies and improve the company's overall profitability.
Investors should monitor Cardinal Health's cash flow metrics closely in future earnings releases to assess the company's progress in addressing this challenge. Sustainable earnings growth requires healthy cash generation, and Cardinal Health must demonstrate its ability to improve its cash flow over time.
Key Takeaways and Strategic Implications:
- Q2 Earnings Beat with Nuances: Cardinal Health's Q2 2025 earnings exceeded expectations, but revenue was impacted by the OptumRx contract expiry. Investors should focus on the company's ability to mitigate this impact through strategic acquisitions and growth in other segments.
- Analyst Confidence and Value Proposition: Analysts are generally positive on Cardinal Health, highlighting its value proposition and raising price targets. This suggests that the stock may be undervalued, but investors should also consider the risks associated with the OptumRx contract expiry and negative cash flow metrics.
- Strategic Acquisitions for Future Growth: The acquisitions of GI Alliance and Advanced Diabetes Supply Group are expected to drive future growth and expand Cardinal Health's presence in key areas of the healthcare market. Successful integration of these acquisitions will be critical to the company's success.
- Dividend Sustainability: Cardinal Health's consistent dividend payouts signal financial stability, but investors should also monitor the company's payout ratio and cash flow metrics to assess the long-term sustainability of the dividend.
- Supply Chain Resilience: Cardinal Health is proactively addressing supply chain challenges by diversifying its sourcing strategies, investing in advanced inventory management systems, and fostering strong relationships with its suppliers. This is essential for ensuring a consistent supply of critical products.
- Adapting to Telehealth and Personalized Medicine: Cardinal Health is actively adapting to the changing healthcare landscape by developing new solutions and services that support telehealth providers and patients, and by investing in capabilities to support personalized medicine.
- Cash Flow Improvement: Addressing negative cash flow is a key priority for Cardinal Health. Investors should monitor the company's progress in implementing strategies to improve its cash flow, such as optimizing working capital management and reducing capital expenditures.
Financial Metrics Table:
| Metric | Value | Source |
|---|---|---|
| Stock Price (Feb 21, 2025) | $128.415 | Monexa AI |
| Revenue Decrease | 4% | Monexa AI |
| Non-GAAP Diluted EPS Increase | 2% to $1.93 | Monexa AI |
| Dividend Yield (Approximate) | 1.57% | Monexa AI |
| Payout Ratio (Approximate) | 37.7% | Monexa AI |
| Operating Cash Flow per Share | -0.0785 | Monexa AI |
| Free Cash Flow per Share | -2.119 | Monexa AI |
Analyst Estimates Table:
| Analyst | Metric | Estimate | Source |
|---|---|---|---|
| Benzinga | EPS View 2025 | Increased | Benzinga.com |
| UBS Group | Price Target | $139 | MarketBeat.com |
| Zacks.com | Stock Assessment | Undervalued | Zacks.com |
| Cardinal Health | FY25 Non-GAAP EPS Guidance | $7.85-$8.00 | Cardinal Health Q2 2025 Earnings Release |